Mineralocorticoid receptor antagonists for heart failure

Noemi Bruno, Gianfranco Sinagra, Stefania Paolillo, Alice Bonomi, Ugo Corrà, Massimo Piepoli, Fabrizio Veglia, Elisabetta Salvioni, Rocco Lagioia, Marco Metra, Giuseppe Limongelli, Gaia Cattadori, Angela B. Scardovi, Valentina Carubelli, Domenico Scrutino, Roberto Badagliacca, Marco Guazzi, Rosa Raimondo, Piero Gentile, Damiano MagrìMichele Correale, Gianfranco Parati, Federica Re, Mariantonietta Cicoira, Maria Frigerio, Maurizio Bussotti, Carlo Vignati, Fabrizio Oliva, Alessandro Mezzani, Giuseppe Vergaro, Andrea Di Lenarda, Claudio Passino, Susanna Sciomer, Giuseppe Pacileo, Roberto Ricci, Mauro Contini, Anna Apostolo, Pietro Palermo, Massimo Mapelli, Cosimo Carriere, Francesco Clemenza, Simone Binno, Romualdo Belardinelli, Carlo Lombardi, Pasquale Perrone Filardi, Michele Emdin, Piergiuseppe Agostoni

Research output: Contribution to journalArticle

Abstract

Aims: Mineralocorticoid receptor antagonists (MRAs) have been demonstrated to improve outcomes in reduced ejection fraction heart failure (HFrEF) patients. However, MRAs added to conventional treatment may lead to worsening of renal function and hyperkalaemia. We investigated, in a population-based analysis, the long-term effects of MRA treatment in HFrEF patients. Methods and results: We analysed data of 6046 patients included in the Metabolic Exercise Cardiac Kidney Index score dataset. Analysis was performed in patients treated (n = 3163) and not treated (n = 2883) with MRA. The study endpoint was a composite of cardiovascular death, urgent heart transplantation, or left ventricular assist device implantation. Ten years' survival was analysed through Kaplan–Meier, compared by log-rank test and propensity score matching. At 10 years' follow-up, the MRA-untreated group had a significantly lower number of events than the MRA-treated group (P 
Original languageEnglish
Pages (from-to)267-274
Number of pages8
JournalESC heart failure
Volume5
Issue number3
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Mineralocorticoid Receptor Antagonists
Heart Failure
Kidney
Propensity Score
Hyperkalemia
Heart-Assist Devices
Heart Transplantation
Exercise
Survival
Therapeutics
Population

Keywords

  • Heart failure
  • Hyperkalaemia
  • Mineralocorticoid receptor antagonists
  • Worsening renal function

Cite this

Bruno, N., Sinagra, G., Paolillo, S., Bonomi, A., Corrà, U., Piepoli, M., ... Agostoni, P. (2018). Mineralocorticoid receptor antagonists for heart failure. ESC heart failure, 5(3), 267-274. https://doi.org/10.1002/ehf2.12244

Mineralocorticoid receptor antagonists for heart failure. / Bruno, Noemi; Sinagra, Gianfranco; Paolillo, Stefania; Bonomi, Alice; Corrà, Ugo; Piepoli, Massimo; Veglia, Fabrizio; Salvioni, Elisabetta; Lagioia, Rocco; Metra, Marco; Limongelli, Giuseppe; Cattadori, Gaia; Scardovi, Angela B.; Carubelli, Valentina; Scrutino, Domenico; Badagliacca, Roberto; Guazzi, Marco; Raimondo, Rosa; Gentile, Piero; Magrì, Damiano; Correale, Michele; Parati, Gianfranco; Re, Federica; Cicoira, Mariantonietta; Frigerio, Maria; Bussotti, Maurizio; Vignati, Carlo; Oliva, Fabrizio; Mezzani, Alessandro; Vergaro, Giuseppe; Di Lenarda, Andrea; Passino, Claudio; Sciomer, Susanna; Pacileo, Giuseppe; Ricci, Roberto; Contini, Mauro; Apostolo, Anna; Palermo, Pietro; Mapelli, Massimo; Carriere, Cosimo; Clemenza, Francesco; Binno, Simone; Belardinelli, Romualdo; Lombardi, Carlo; Perrone Filardi, Pasquale; Emdin, Michele; Agostoni, Piergiuseppe.

In: ESC heart failure, Vol. 5, No. 3, 01.01.2018, p. 267-274.

Research output: Contribution to journalArticle

Bruno, N, Sinagra, G, Paolillo, S, Bonomi, A, Corrà, U, Piepoli, M, Veglia, F, Salvioni, E, Lagioia, R, Metra, M, Limongelli, G, Cattadori, G, Scardovi, AB, Carubelli, V, Scrutino, D, Badagliacca, R, Guazzi, M, Raimondo, R, Gentile, P, Magrì, D, Correale, M, Parati, G, Re, F, Cicoira, M, Frigerio, M, Bussotti, M, Vignati, C, Oliva, F, Mezzani, A, Vergaro, G, Di Lenarda, A, Passino, C, Sciomer, S, Pacileo, G, Ricci, R, Contini, M, Apostolo, A, Palermo, P, Mapelli, M, Carriere, C, Clemenza, F, Binno, S, Belardinelli, R, Lombardi, C, Perrone Filardi, P, Emdin, M & Agostoni, P 2018, 'Mineralocorticoid receptor antagonists for heart failure', ESC heart failure, vol. 5, no. 3, pp. 267-274. https://doi.org/10.1002/ehf2.12244
Bruno N, Sinagra G, Paolillo S, Bonomi A, Corrà U, Piepoli M et al. Mineralocorticoid receptor antagonists for heart failure. ESC heart failure. 2018 Jan 1;5(3):267-274. https://doi.org/10.1002/ehf2.12244
Bruno, Noemi ; Sinagra, Gianfranco ; Paolillo, Stefania ; Bonomi, Alice ; Corrà, Ugo ; Piepoli, Massimo ; Veglia, Fabrizio ; Salvioni, Elisabetta ; Lagioia, Rocco ; Metra, Marco ; Limongelli, Giuseppe ; Cattadori, Gaia ; Scardovi, Angela B. ; Carubelli, Valentina ; Scrutino, Domenico ; Badagliacca, Roberto ; Guazzi, Marco ; Raimondo, Rosa ; Gentile, Piero ; Magrì, Damiano ; Correale, Michele ; Parati, Gianfranco ; Re, Federica ; Cicoira, Mariantonietta ; Frigerio, Maria ; Bussotti, Maurizio ; Vignati, Carlo ; Oliva, Fabrizio ; Mezzani, Alessandro ; Vergaro, Giuseppe ; Di Lenarda, Andrea ; Passino, Claudio ; Sciomer, Susanna ; Pacileo, Giuseppe ; Ricci, Roberto ; Contini, Mauro ; Apostolo, Anna ; Palermo, Pietro ; Mapelli, Massimo ; Carriere, Cosimo ; Clemenza, Francesco ; Binno, Simone ; Belardinelli, Romualdo ; Lombardi, Carlo ; Perrone Filardi, Pasquale ; Emdin, Michele ; Agostoni, Piergiuseppe. / Mineralocorticoid receptor antagonists for heart failure. In: ESC heart failure. 2018 ; Vol. 5, No. 3. pp. 267-274.
@article{f354a1c0d90746db8d00e88a4c65cfee,
title = "Mineralocorticoid receptor antagonists for heart failure",
abstract = "Aims: Mineralocorticoid receptor antagonists (MRAs) have been demonstrated to improve outcomes in reduced ejection fraction heart failure (HFrEF) patients. However, MRAs added to conventional treatment may lead to worsening of renal function and hyperkalaemia. We investigated, in a population-based analysis, the long-term effects of MRA treatment in HFrEF patients. Methods and results: We analysed data of 6046 patients included in the Metabolic Exercise Cardiac Kidney Index score dataset. Analysis was performed in patients treated (n = 3163) and not treated (n = 2883) with MRA. The study endpoint was a composite of cardiovascular death, urgent heart transplantation, or left ventricular assist device implantation. Ten years' survival was analysed through Kaplan–Meier, compared by log-rank test and propensity score matching. At 10 years' follow-up, the MRA-untreated group had a significantly lower number of events than the MRA-treated group (P ",
keywords = "Heart failure, Hyperkalaemia, Mineralocorticoid receptor antagonists, Worsening renal function",
author = "Noemi Bruno and Gianfranco Sinagra and Stefania Paolillo and Alice Bonomi and Ugo Corr{\`a} and Massimo Piepoli and Fabrizio Veglia and Elisabetta Salvioni and Rocco Lagioia and Marco Metra and Giuseppe Limongelli and Gaia Cattadori and Scardovi, {Angela B.} and Valentina Carubelli and Domenico Scrutino and Roberto Badagliacca and Marco Guazzi and Rosa Raimondo and Piero Gentile and Damiano Magr{\`i} and Michele Correale and Gianfranco Parati and Federica Re and Mariantonietta Cicoira and Maria Frigerio and Maurizio Bussotti and Carlo Vignati and Fabrizio Oliva and Alessandro Mezzani and Giuseppe Vergaro and {Di Lenarda}, Andrea and Claudio Passino and Susanna Sciomer and Giuseppe Pacileo and Roberto Ricci and Mauro Contini and Anna Apostolo and Pietro Palermo and Massimo Mapelli and Cosimo Carriere and Francesco Clemenza and Simone Binno and Romualdo Belardinelli and Carlo Lombardi and {Perrone Filardi}, Pasquale and Michele Emdin and Piergiuseppe Agostoni",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/ehf2.12244",
language = "English",
volume = "5",
pages = "267--274",
journal = "ESC heart failure",
issn = "2055-5822",
publisher = "Wiley Blackwell",
number = "3",

}

TY - JOUR

T1 - Mineralocorticoid receptor antagonists for heart failure

AU - Bruno, Noemi

AU - Sinagra, Gianfranco

AU - Paolillo, Stefania

AU - Bonomi, Alice

AU - Corrà, Ugo

AU - Piepoli, Massimo

AU - Veglia, Fabrizio

AU - Salvioni, Elisabetta

AU - Lagioia, Rocco

AU - Metra, Marco

AU - Limongelli, Giuseppe

AU - Cattadori, Gaia

AU - Scardovi, Angela B.

AU - Carubelli, Valentina

AU - Scrutino, Domenico

AU - Badagliacca, Roberto

AU - Guazzi, Marco

AU - Raimondo, Rosa

AU - Gentile, Piero

AU - Magrì, Damiano

AU - Correale, Michele

AU - Parati, Gianfranco

AU - Re, Federica

AU - Cicoira, Mariantonietta

AU - Frigerio, Maria

AU - Bussotti, Maurizio

AU - Vignati, Carlo

AU - Oliva, Fabrizio

AU - Mezzani, Alessandro

AU - Vergaro, Giuseppe

AU - Di Lenarda, Andrea

AU - Passino, Claudio

AU - Sciomer, Susanna

AU - Pacileo, Giuseppe

AU - Ricci, Roberto

AU - Contini, Mauro

AU - Apostolo, Anna

AU - Palermo, Pietro

AU - Mapelli, Massimo

AU - Carriere, Cosimo

AU - Clemenza, Francesco

AU - Binno, Simone

AU - Belardinelli, Romualdo

AU - Lombardi, Carlo

AU - Perrone Filardi, Pasquale

AU - Emdin, Michele

AU - Agostoni, Piergiuseppe

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aims: Mineralocorticoid receptor antagonists (MRAs) have been demonstrated to improve outcomes in reduced ejection fraction heart failure (HFrEF) patients. However, MRAs added to conventional treatment may lead to worsening of renal function and hyperkalaemia. We investigated, in a population-based analysis, the long-term effects of MRA treatment in HFrEF patients. Methods and results: We analysed data of 6046 patients included in the Metabolic Exercise Cardiac Kidney Index score dataset. Analysis was performed in patients treated (n = 3163) and not treated (n = 2883) with MRA. The study endpoint was a composite of cardiovascular death, urgent heart transplantation, or left ventricular assist device implantation. Ten years' survival was analysed through Kaplan–Meier, compared by log-rank test and propensity score matching. At 10 years' follow-up, the MRA-untreated group had a significantly lower number of events than the MRA-treated group (P 

AB - Aims: Mineralocorticoid receptor antagonists (MRAs) have been demonstrated to improve outcomes in reduced ejection fraction heart failure (HFrEF) patients. However, MRAs added to conventional treatment may lead to worsening of renal function and hyperkalaemia. We investigated, in a population-based analysis, the long-term effects of MRA treatment in HFrEF patients. Methods and results: We analysed data of 6046 patients included in the Metabolic Exercise Cardiac Kidney Index score dataset. Analysis was performed in patients treated (n = 3163) and not treated (n = 2883) with MRA. The study endpoint was a composite of cardiovascular death, urgent heart transplantation, or left ventricular assist device implantation. Ten years' survival was analysed through Kaplan–Meier, compared by log-rank test and propensity score matching. At 10 years' follow-up, the MRA-untreated group had a significantly lower number of events than the MRA-treated group (P 

KW - Heart failure

KW - Hyperkalaemia

KW - Mineralocorticoid receptor antagonists

KW - Worsening renal function

U2 - 10.1002/ehf2.12244

DO - 10.1002/ehf2.12244

M3 - Article

VL - 5

SP - 267

EP - 274

JO - ESC heart failure

JF - ESC heart failure

SN - 2055-5822

IS - 3

ER -